vorinostat has been researched along with Cancer of Endometrium in 10 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have reported previously that treatment with HDACIs, including trichostatin A and suberoylanilide hydroxamic acid (SAHA) or progesterone in combination with estrogen, can induce cytodifferentiation of endometrial adenocarcinoma Ishikawa cells through up-regulation of glycodelin, a progesterone-induced endometrial glycoprotein." | 3.74 | Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin. ( Arase, T; Asada, H; Kajitani, T; Maruyama, T; Masuda, H; Nagashima, T; Ohta, K; Ono, M; Uchida, H; Yoshimura, Y, 2007) |
| " In this study, we show that TSA and SAHA, belonging to the hydroxamic acid group of HDACIs, can induce the phenotype of a human endometrial adenocarcinoma cell line, Ishikawa (originally derived from the glandular component of the endometrium), to differentiate to closely resemble normal endometrial epithelium in a time- and dose-dependent manner, as determined by morphological changes, synthesis of glycogen, and expression of secretory phase-specific proteins, including glycodelin." | 3.73 | Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. ( Asada, H; Maruyama, T; Nagashima, T; Uchida, H; Yoshimura, Y, 2005) |
| "Endometrial stromal sarcomas are rare and molecular mechanisms involved in their pathogenesis are poorly understood." | 1.35 | SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. ( Denk, H; Hrzenjak, A; Kremser, ML; Moinfar, F; Strohmeier, B; Zatloukal, K, 2008) |
| "Endometrial and ovarian cancer cells were treated with various concentrations of M344, and its effect on cell growth, cell cycle, apoptosis, and related measurements was investigated." | 1.33 | M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells. ( Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergadà , L | 2 |
| Sorolla, A | 2 |
| Yeramian, A | 2 |
| Eritja, N | 1 |
| Mirantes, C | 1 |
| Matias-Guiu, X | 2 |
| Dolcet, X | 2 |
| Ren, J | 1 |
| Zhang, J | 1 |
| Cai, H | 1 |
| Li, Y | 1 |
| Zhang, Y | 1 |
| Zhang, X | 1 |
| Zhao, D | 1 |
| Li, Z | 1 |
| Ma, H | 1 |
| Wang, J | 1 |
| Gao, YE | 1 |
| Xiao, L | 1 |
| Liu, R | 1 |
| Qian, J | 1 |
| Liu, Y | 1 |
| Wei, H | 1 |
| Li, J | 1 |
| Hrzenjak, A | 1 |
| Kremser, ML | 1 |
| Strohmeier, B | 1 |
| Moinfar, F | 1 |
| Zatloukal, K | 1 |
| Denk, H | 1 |
| Sarfstein, R | 1 |
| Bruchim, I | 1 |
| Fishman, A | 1 |
| Werner, H | 1 |
| Mendivil, AA | 1 |
| Micha, JP | 1 |
| Brown, JV | 1 |
| Rettenmaier, MA | 1 |
| Abaid, LN | 1 |
| Lopez, KL | 1 |
| Goldstein, BH | 1 |
| Takai, N | 2 |
| Desmond, JC | 1 |
| Kumagai, T | 1 |
| Gui, D | 1 |
| Said, JW | 1 |
| Whittaker, S | 1 |
| Miyakawa, I | 1 |
| Koeffler, HP | 1 |
| Uchida, H | 2 |
| Maruyama, T | 2 |
| Nagashima, T | 2 |
| Asada, H | 2 |
| Yoshimura, Y | 2 |
| Ueda, T | 1 |
| Nishida, M | 1 |
| Nasu, K | 1 |
| Narahara, H | 1 |
| Ono, M | 1 |
| Ohta, K | 1 |
| Kajitani, T | 1 |
| Masuda, H | 1 |
| Arase, T | 1 |
1 review available for vorinostat and Cancer of Endometrium
| Article | Year |
|---|---|
HDAC as a therapeutic target for treatment of endometrial cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; DNA Methylation; Endometrial Neoplasms; Epigenesis, Genet | 2014 |
1 trial available for vorinostat and Cancer of Endometrium
| Article | Year |
|---|---|
Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous | 2013 |
8 other studies available for vorinostat and Cancer of Endometrium
| Article | Year |
|---|---|
Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 8; Cell Line, Tumor; Endometri | 2013 |
Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation.
Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Caspase 8; Cell Line, Tumor; Cell Survival; | 2014 |
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Topics: Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; | 2008 |
The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Cy | 2011 |
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
Topics: Agar; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cadherins; Cell Cycle Proteins; | 2004 |
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Topics: Adenocarcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; E | 2005 |
M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Topics: Acetylation; Apoptosis; Cadherins; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cyclin-Depen | 2006 |
Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Endometrial Neoplasms; Enzym | 2007 |